24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
CytoReason
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:13
Inside Tower Semiconductor’s strategic shift: why India is now key to its growth
12:44
Israel’s Tower Semiconductor joins forces with Adani for $10 billion India chip project
10:29
Qualcomm eyes Intel's PC design unit to expand chip portfolio
10:13
Intel weighs selling part of Mobileye to raise much-needed capital
More stories
Buzz
Most popular
Daily
Weekly
1
Intel races against time to complete layoffs amid financial losses
2
Salesforce acquires Israeli data company Own for $1.9 billion in cash
3
The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success
4
Intel's layoff plan enters new phase after voluntary retirement program closes
5
OpenAI co-founder Sutskever raises $1B at $5B valuation for safe AI startup
More news
CytoReason
4 stories about CytoReason
CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models
17.07.24
|
Meir Orbach
The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform
20.09.22
|
Meir Orbach
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
CytoReason enters Japanese market with SPI partnership
30.09.21
|
James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason
10.01.19
|
Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars
Please ensure Javascript is enabled for purposes of
website accessibility